miR-17-5p as a Novel Prognostic Marker for Hepatocellular Carcinoma

Chen, Ling; Jiang, Meng; Yuan, Weijie; Tang, Huiqin

doi:10.3109/08941939.2011.618523

Cited by 57 publications

(41 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This miRNA was reported up-regulated in HCC and a novel biomarker in a recently published study [31]. Our finding is also in agreement with this study.…”

Section: Discussionsupporting

confidence: 95%

Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma

et al. 2014

View full text Add to dashboard Cite

Recently, serum miRNAs have been evolved as possible biomarkers for different diseases including hepatocellular carcinoma and other types of cancers. Investigating certain serum miRNAs as novel non-invasive markers for early detection of HCV-positive cirrhosis and hepatocellular carcinoma (HCC). The expression profiles of 58 miRNA were analyzed in patient's plasma of chronic hepatitis C (CHC), HCV-positive cirrhosis and HCV-positive HCC and compared with control group samples. Totally 94 plasma samples; 64 patient plasma (26 CHC, 30 HCV-positive cirrhosis, 8 HCV-positive HCC) and 28 control group plasma, were included. The expression profiles of 58 miRNAs were detected for all patient and control group plasma samples by qRT-PCR using BioMarkTM 96.96 Dynamic Array (Fluidigm Corporation) system. In CHC group, expression profiles of miR-30a-5p, miR-30c-5p, miR-206 and miR-302c-3p were found significantly deregulated (p < 0.05) when compared versus control group. In HCV-positive cirrhosis group, expression profiles of miR-30c-5p, miR-223-3p, miR-302c-3p, miR-17-5p, miR-130a-3p, miR-93-5p, miR-302c-5p and miR-223-3p were found significantly deregulated (p < 0.05). In HCV-positive HCC group, expression profiles of miR-17-5p, miR-223-3p and miR-24-3p were found significant (p < 0.05). When all groups were compared versus control, miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p were found significantly deregulated for cirrhosis and HCC. These results imply that miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at cirrhosis stage of liver disease.

show abstract

“…This miRNA was reported up-regulated in HCC and a novel biomarker in a recently published study [31]. Our finding is also in agreement with this study.…”

Section: Discussionsupporting

confidence: 95%

Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…But on the other hand, it contradicts other studies that reported reduced IGFBP-3 mRNA expression and protein levels in metastatic HCC patients [12,13] . Moreover, the repression of miR-17-5p in HCC tissues ( Figure 1A) corroborates our previous results that showed a significant downregulation of miR-17-5p expression in non-metasatic HCC patients [20] , but nonetheless it contradicts other studies in metastatic HCC tissues [23] . These disparities can, however, be attributed to differences in the cohorts of patients included in the various studies, with regards to stage and etiology of the disease as well as other factors such as ethnicity, gender and age.…”

Section: Discussionsupporting

confidence: 71%

Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma

Habashy¹,

Tayebi²,

Fawzy³

et al. 2016

WJH

View full text Add to dashboard Cite

AIM:To investigate the effect of microRNA on insulinlike growth factor binding protein-3 (IGFBP-3) and hence on insulin-like growth factor-Ⅱ (IGF-Ⅱ) bioavailability in hepatocellular carcinoma (HCC). METHODS:Bioinformatic analysis was performed using microrna.org, DIANA lab and Segal lab softwares. Total RNA was extracted from 23 HCC and 10 healthy liver tissues using mirVana miRNA Isolation Kit. microRNA-17-5p (miR-17-5p) expression was mimicked and antagonized in HuH-7 cell lines using HiPerFect Basic Study 977August 18, 2016|Volume 8|Issue 23| WJH|www.wjgnet.comHabashy DA et al . miR-17-5p regulates IGF-Ⅱ via targeting IGFBP-3 Transfection Reagent, then total RNA was extracted using Biozol reagent then reverse transcribed into cDNA followed by quantification of miR-17-5p and IGFBP-3 expression using TaqMan real-time quantitative PCR. Luciferase reporter assay was performed to validate the binding of miR-17-5p to the 3'UTR of IGFBP-3. Free IGF-Ⅱ protein was measured in transfected HuH-7 cells using IGF-Ⅱ ELISA kit. RESULTS:Bioinformatic analysis revealed IGFBP-3 as a potential target for miR-17-5p. Screening of miR-17-5p and IGFBP-3 revealed a moderate negative correlation in HCC patients, where miR-17-5p was extensively underexpressed in HCC tissues (P = 0.0012), while IGFBP-3 showed significant upregulation in the same set of patients (P = 0.0041) compared to healthy donors. Forcing miR-17-5p expression in HuH-7 cell lines showed a significant downregulation of IGFBP-3 mRNA expression (P = 0.0267) and a significant increase in free IGF-Ⅱ protein (P = 0.0339) compared to mock untransfected cells using unpaired t -test. Luciferase assay validated IGFBP-3 as a direct target of miR-17-5p; luciferase activity was inhibited by 27.5% in cells co-transfected with miR-17-5p mimics and the construct harboring the wild-type binding region 2 of IGFBP-3 compared to cells transfected with this construct alone (P = 0.0474). CONCLUSION:These data suggest that regulating IGF-Ⅱ bioavailability and hence HCC progression can be achieved through targeting IGFBP-3 via manipulating the expression of miRNAs.

show abstract

“…In tissues, with regard to up-regulated microRNAs in HCC tissues, highly expression of miR-106b-5p, miR-155-5p, miR-17-5p, miR-182-5p, miR-183-5p, miR-18b-5p, miR-21-5p, miR-25-3p, miR-331-3p, miR-9-5p and miR-96-5p were significantly correlated with invasion and metastasis454752566465666768697071. The expression level of miR-1269a in HCC patients without portal vein tumor embolus was reduced72.…”

Section: Resultsmentioning

confidence: 99%

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

Shen

Lin

Yuan

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Hepatocellular Carcinoma (HCC) is one of the most common malignant tumors with high incidence and mortality rate. Precision and effective biomarkers are therefore urgently needed for the early diagnosis and prognostic estimation. MicroRNAs (miRNAs) are important regulators which play functions in various cellular processes and biological activities. Accumulating evidence indicated that the abnormal expression of miRNAs are closely associated with HCC initiation and progression. Recently, many biomarker miRNAs for HCC have been identified from blood or tissues samples, however, the universality and specificity on clinicopathological features of them are less investigated. In this review, we comprehensively surveyed and compared the diagnostic, prognostic, and therapeutic roles of HCC biomarker miRNAs in blood and tissues based on the cancer hallmarks, etiological factors as well as ethnic groups, which will be helpful to the understanding of the pathogenesis of biomarker miRNAs in HCC development and further provide accurate clinical decisions for HCC diagnosis and treatment.

show abstract

miR-17-5p as a Novel Prognostic Marker for Hepatocellular Carcinoma

Abstract: miR-17-5p is highly elevated in HCC, especially in HCC with metastasis. miR-17-5p can serve as a novel prognostic marker for HCC.

Cited by 57 publications

References 31 publications

Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma

Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma

Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

Contact Info

Product

Resources

About